spacer
home > ebr > winter 2020 > a viable solution
PUBLICATIONS
European Biopharmaceutical Review

A Viable Solution




Sepsis is a specific condition itself but is mainly caused by bacterial infection in blood. Gram-positive bacterial infection is the most common cause of sepsis, although the incidence of gram-negative and fungal infections is increasing. The most common sites of infection leading to sepsis are the lungs, urinary tract, abdomen, and pelvis. Other sources of infection leading to sepsis include skin infections (such as cellulitis), post-surgical infections, and infections of the nervous system (such as meningitis or encephalitis) (1).

It is also worth noting the incidence of sepsis is increasing in all areas of the world where epidemiology studies have been conducted, and despite falling proportional fatality rates, the total number of people dying with sepsis each year continues to increase due to the growing number of cases (2).

Today, the use of standard blood culture techniques for the detection and isolation of pathogenic organisms from a sterile body fluid sample is still considered the gold standard for diagnosis of infection and sepsis. Unfortunately, routine blood culture can take anywhere from five hours to six days to grow an organism to detectable levels, and additional time (24-48 hours) is required to identify and test for antibiotic resistance.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jan Rogers is Chief Scientific Officer at Arcis Biotechnology and has been with the company for eight years. She has previously held senior positions with SSL International, Convatec, and Molnlycke. Jan has a PhD in Chemistry and also holds an MBA from the University of Bath, UK.

Dr Pablo Castan obtained his degree in Biology and PhD in Molecular Biology from Universidad Autonoma de Madrid, Spain, and also has a degree in Molecular Medicine from the University of East Anglia, UK. He is currently Associate Investigator in the Department of Microbiology at Hospital Carlos III, Spain, and the Research Director for Arcis Biotechnology.
spacer
Jan Rogers
spacer
spacer
spacer
Dr Pablo Castan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement